|
|
Title:
Hydrolytically degradable polymers and hydrogels made therefrom
United States Patent: 7,772,357
Issued: August 10, 2010
Inventors: Harris; J.
Milton (Huntsville, AL), Bentley; Michael D. (Huntsville, AL), Zhao; Xuan
(Beijing, CN), Shen; Xiaoming (Madison, AL)
Assignee: Nektar
Therapeutics (San Carlos, CA)
Appl. No.: 12/559,162
Filed: September 14, 2009
|
|
|
George Washington University's Healthcare MBA
|
Abstract
A water soluble polymer comprising
multiple degradable carbonate linkages in a backbone and, for each
carbonate linkage in the backbone, an oligomer linked thereto by the
carbonate linkage, wherein the oligomer is branched.
Description of the
Invention
SUMMARY OF THE INVENTION
This invention provides a water soluble, nonpeptidic polymer having two or
more oligomers linked together by hydrolytically degradable carbonate
linkages. The polymer can be hydrolytically degraded into small oligomers
in an aqueous environment, including in vivo conditions. The polymer is
easy to prepare and the molecular weight of the oligomers resulting from
polymer degradation can be easily controlled, which can be desirable for
some applications. The polymer can be conjugated to a biologically active
agent such as a protein or peptide. The polymer can impart desirable
characteristics to the conjugates of improved water solubility and reduced
immunogenicity. The polymer is useful for preparing insoluble cross linked
structures, including hydrogels, that are hydrolytically degradable into
soluble polymers of predetermined molecular weight.
The oligomers are alkylene oxide oligomers. Typically, the oligomers are
ethylene oxide oligomers, and the polymer is a poly(ether carbonate)
having the formula of: HO--[(--CH.sub.2CH.sub.2O).sub.n--CO.sub.2].sub.m--(--CH.sub.2CH.sub.2--O-
).sub.nH where n is from about 1 to 2,000, normally from 2 to 2,000, and m
is from about 2 to 200. Since carbonate linkages are hydrolytically
degradable under mild conditions, the polymer will hydrolyze to produce
oligomer fragments of much lower molecular weight than the starting
polymer: HO--[(--CH.sub.2CH.sub.2O).sub.n--CO.sub.2].sub.m--(--CH.sub.2CH-
.sub.2--O).sub.nH+(m+1)H.sub.2O.fwdarw.(m+1)HO--(--CH.sub.2CH.sub.2--O--).-
sub.n--H+mCO.sub.2
In addition to providing many of the desirable features of other polymers,
including poly(ethylene glycol) as described above, this new polymer can
degrade in the body and thus facilitates removal of the polymer from the
body. The degradation products are themselves normally nontoxic small PEGs
that typically are rapidly cleared from the body.
The polymer can be prepared in a number of ways. In one embodiment of this
invention, the poly(ether carbonate) is prepared by polymerizing an
activated oligomer having the formula of:
HO--(--CH.sub.2CH.sub.2O).sub.n--CO.sub.2--Z where n can be from about 2
to 2000 and Z is a reactive leaving group such as N-succinimidyl,
1-benzotriazolyl, or p-nitrophenyl.
The polymer can be prepared by polymerizing ethylene oxide oligomers of
the formula: HO--(--CH.sub.2CH.sub.2O).sub.n--H where n can be from about
2 to 2000 with an activating molecule of Z--O--CO.sub.2--Z, where Z is as
described.
Alternatively, the ethylene oxide oligomer HO--(--CH.sub.2CH.sub.2O).sub.n--H
can be polymerized with a bifunctional ethylene oxide oligomer:
Z--OCO.sub.2--(--CH.sub.2CH.sub.2--O--).sub.n--CO.sub.2--Z where n and Z
are as described above, to form the poly(ether carbonate).
The polymerization reactions may be conducted either in an organic solvent
or in a melt, in the presence of an organic base. Examples of suitable
solvents include acetonitrile, THF, dimethylformamide, dimethylsulfoxide,
benzene, toluene, the xylenes, chloroform, and methylene chloride.
Examples of suitable organic bases include triethylamine, pyridine,
quinoline, 4,4-dimethylaminopyridine and triethylamine. The polymerization
reactions can be conducted at a temperature of from about 37.degree. C. to
100.degree. C., typically from about 45.degree. C. to 100.degree. C., and
advantageously from about 70.degree. C. to 90.degree. C.
The polymer of this invention can be modified at one terminus with alkyl
or aryl groups to make one end of the polymer inert. The polymer can be
activated at one or more of its termini to form a terminal reactive
moiety. Thus, a modified or activated poly(ether carbonate) of this
invention can be represented as: X--O--[(CH.sub.2CH.sub.2--O).sub.n--CO.sub.2].sub.m--(CH.sub.2CH.sub.2--O-
).sub.n--Y where m and n are as defined above, and where X and Y can
independently be H, alkyl, alkenyl, aryl, and reactive terminal moieties,
including N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl,
or others. Alternatively, X and Y can include linker groups terminating in
active groups such as aldehyde N-maleimidyl or --S--S-orthopyridyl. A wide
variety of activating groups and linkers can be used.
The activated polymer of this invention can be reacted with an active
group on a biologically active agent, such as a protein or peptide, to
form a conjugate. For example, N-succinimiayloxy, 1-benzotriazolyloxy, and
p-nitrophenyloxy are leaving groups suitable for the formation of a
carbamate linkage between the polymer and a biologically active agent
having an amino group. Thus proteins, peptides, amino drugs or amino
carbohydrates can be linked to such activated polymers. For example, when
X is H, and Y is N-succinimidyloxycarbonyl, a conjugate can be formed of
the following formula: HO--[(CH.sub.2CH.sub.2--O).sub.n--CO.sub.2].sub.m--(CH.sub.2CH.sub.2--O).-
sub.n--CONH-Protein
When a protein to be conjugated has an accessible thiol group, the polymer
of this invention can be activated to contain a terminal reactive moiety
that is reactive with thiol, including, for example, iodoacetamide,
vinylsulfone, maleimide, or S--S-ortho-pyridyl, which moiety is then
reacted with the thiol group to form a thiol site-specific conjugate of
the protein.
When the polymer of this invention is activated at two termini, it can be
used as a crosslinking agent to crosslink a multifunctional molecule to
form a hydrolytically degradable hydrogel. Examples of multifunctional
molecules suitable as "backbones" in formation of hydrogels include
proteins such as collagen, aminocarbohydrates such as chitosan, polyamines
such as polylysine and poly(vinylamine), and multi-armed or branched
poly(ethylene glycol) amines. The hydrogels of this invention are useful
in many biomedical applications such as drug delivery, surgical adhesion
prevention, wound and scar healing, bioadhesives and surgical implants.
In another embodiment, the polymer of this invention can be activated by
attachment of terminal vinyl groups. This activated polymer can be
self-polymerized in the presence of a conventional vinyl polymerization
catalyst to form a hydrolytically degradable hydrogel.
Thus, this invention provides a versatile polymer that is especially
suited for conjugating to a biologically active agent and for forming a
hydrogel. The polymer is easy to prepare and can be synthesized in large
quantities. The polymer can be formed in a single reaction with multiple
degradable carbonate linkages in the backbone. The conjugate and hydrogel
of this invention can be degraded under physiological conditions. The
degradation generates oligomers of predetermined molecular weight that can
be easily cleared from the body.
The foregoing and other advantages and features of the invention, and the
manner in which the same are accomplished, will become more readily
apparent upon consideration of the following detailed description of the
invention taken in conjunction with the accompanying examples, which
illustrate preferred and exemplary embodiments.
DETAILED DESCRIPTION OF THE INVENTION
The oligomers used in the practice of the invention should be selected so
that they and the degradation products of the polymer of this invention
are water soluble and can easily be excreted from animal bodies under
natural physiological conditions. They should be non-toxic, or at least of
acceptable low toxicity, and should not cause a substantial adverse effect
in human or animal bodies.
Many different types of alkylene oxide oligomers are useful in forming the
polymer of this invention. In its simplest form, an alkylene oxide "homo-oligomer"
is used having the formula of HO--(--CHRCH.sub.2--O).sub.n--H, where R is
H or an alkyl, including methyl. Suitable oligomers also include alkylene
oxide "co-oligomers," which are composed of different alkylene oxide
monomers in which R is varied independently along the chain. An example of
a co-oligomer is a structure in which two different R groups are present
in a block such as HO--(--CHR.sub.1CH.sub.2--O--).sub.n--(--CHR.sub.2CH.sub.2--O--).sub.n--H-
, where n and m can be varied independently. An example of this type of
block structure is the case in which R.sub.1 is hydrogen and R.sub.2 is
methyl.
Block oligomers can exhibit surface activity. Degradable surfactants are
useful in drug delivery systems and can be used to form micelles and
thermally reversible gels. Random oligomers in which R.sub.1 and R.sub.2
are randomly placed along the oligomer chain are also useful. The
oligomers can be branched, as in the formula
R.sub.3[O--(--CHR.sub.1CH.sub.2--O--).sub.n--].sub.mH
where R.sub.3 is a core branching moiety, including glycerol or
pentaerythritol, R.sub.1 is alkyl n can range from 2 to hundreds, and m is
at least 3.
A suitable oligomer can be formed from about 2 to 2000 monomers. However,
the size of the oligomers used can vary so long as the above requirements
are met. Normally an oligomer has from about 5 to 500 monomers.
Advantageously, an oligomer has from about 10 to 50 monomers. An oligomer
can be prepared by polymerizing or co-polymerizing monomers, and the size
or molecular weight of the oligomer can be controlled by limiting the
extent of this polymerization reaction.
As noted above, the oligomers contained in the polymer of this invention
can be the same or different types of oligomers, or oligomers of the same
type but different sizes. Therefore, the polymer of this invention can be
either a homopolymer or heteropolymer.
The polymer of this invention typically has one single linear polymer
backbone with two termini. However, branched polymers and star polymers
are also contemplated that have two or more linear polymers, at least one
of which is the linear polymer backbone of this invention, covalently
linked to a central branching core.
The polymer of this invention can have an inert terminal moiety, typically
H, alkyl, and aryl. The alkyl and aryl groups can be substituted or
unsubstituted, and normally are methyl, ethyl, phenyl, etc. The polymer
can also have one or more reactive moieties capable of reacting with a
moiety in another molecule, such as an amino group or a thiol group on a
protein. Examples of such reactive moieties include, but are not limited
to, acryloyl, alkenyl, tresyl, N-succinimidyloxycarbonyl,
1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl,
aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, o-pyridyldithiyl,
and the like.
In one embodiment of this invention, the hydrolytically degradable polymer
is a poly(ether carbonate) composed of two or more alkylene oxide
oligomers and/or alkylene oxide monomers covalently linked together by
carbonate linkages. For example, the poly(ether carbonate) can have the
formula of X--O--{[(R.sub.1--O).sub.a--CO.sub.2--].sub.h--[(R.sub.2--O).sub.b--CO.su-
b.2--].sub.i}.sub.m--{[(R.sub.3--O).sub.c--CO.sub.2--].sub.j--[(R.sub.4--O-
).sub.d--CO.sub.2--].sub.k}--(R.sub.5--O).sub.e--Y wherein R.sub.1,
R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are alkyl groups which may be
linear, branched, substituted or unsubstituted, and they can be same or
different; typically R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are
ethyl; a, b, c, d, e each is an integer of from 1 to about 2000, normally
from about 5 to 500, and advantageously from about 10 to 50; h, i, j, and
k each is an integer of from 0 to about 100, and the sum of h, i, j, and k
is from about 2 to 200, normally from about 5 to 100, and advantageously
from about 10 to 50; and each of X and Y is hydrogen, alkyl, alkenyl,
aryl, or reactive moieties as described above, and X and Y can be same or
different.
In a preferred embodiment, the poly(ether carbonate) of this invention has
the formula of: X--O--[(--CH.sub.2CH.sub.2--O--).sub.n--CO.sub.2--].sub.m--(CH.sub.2CH.su-
b.2O).sub.n--Y wherein n is an integer of from about 2 to 2000, normally
from about 5 to 500, and advantageously from about 10 to 50; m is an
integer of from about 2 to 100, typically from about 5 to 100, and
advantageously from about 10 to 50, and wherein X and Y can be same or
different and each independently is H, alkyl, alkenyl, aryl, or a reactive
moiety, acryloyl, tresyl, N-succinimidyloxycarbonyl,
1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl,
aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and
o-pyridyldithiyl.
This specific form of poly(ether carbonate) contains repeating ethylene
oxide oligomers linked by carbonate linkages that can be hydrolytically
cleaved. Such hydrolytic cleavage leads to ethylene oxide oligomers and
carbon dioxide. Therefore, the poly(ether carbonate) differs substantially
from poly(ethylene glycol) or PEG in having multiple degradable backbone
carbonate linkages that allow the polymer to be broken down into many
smaller oligomers. Since the rate of degradation of the polymer is
proportional to the number of degradable carbonate linkages present and
since the size and number of the oligomers can be predetermined,
substantial control over both degradation rate and the size of the
degradation products is thus possible.
To prepare polymers of the invention, in one example, one or more
oligomers as described above are provided each having a hydroxyl group at
one terminus and a functional group of --O--CO.sub.2--Z at another
terminus. The oligomers are then polymerized or co-polymerized in a
condensation polymerization reaction under conditions sufficient to form a
hydrolytically degradable polymer.
The functional group --O--CO.sub.2--Z is capable of reacting with a
hydroxyl group to form a carbonate linkage. Typically, Z can be any
reactive leaving groups so long as the functional group can react with a
hydroxyl group to form a carbonate linkage. Examples of suitable leaving
groups include N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl.
Methods for preparing an oligomer having a functional group
--O--CO.sub.2--Z as described above are well known in the art, and are
disclosed in U.S. Pat. Nos. 5,650,234, 5,281,698 and 5,468,478; Veronese,
et al, Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl.
Biochem. Biotech., 27:45 (1991), all of which are incorporated herein by
reference.
As discussed above, one or more types of oligomers can be polymerized
together. In addition, if desired, monomers having a hydroxyl terminus and
a functional group --O--CO.sub.2--Z at another terminus, can also be
included in the polymerization mixture.
Thus, to give an example, the poly(ether carbonate)
HO--[(--CH.sub.2CH.sub.2--O--).sub.n--CO.sub.2--].sub.m--(CH.sub.2CH.sub.-
2O).sub.n--H as described above can be prepared in accordance with this
method by the following steps. First, an ethylene oxide oligomer is
provided having a formula of HO--(--CH.sub.2CH.sub.2--O--).sub.n--O--CO.sub.2--Z,
where Z is a reactive leaving group such as N-succinimidyl,
1-benzotriazolyl, and p-nitrophenyl. This oligomer is then polymerized
under controlled conditions to provide the above poly(ether carbonate).
In another example of this invention, a first oligomer is provided, which
is a bifunctional oligomer having a first functional group of
--O--CO.sub.2--W at one terminus and, at another terminus, a second
functional group of --O--CO.sub.2--Z. Both functional groups are capable
of reacting with a hydroxyl group to form a carbonate linkage. Z and W are
reactive leaving groups, and can be any leaving groups known in the art so
long as the functional groups containing them, as stated above, are
capable of reacting with a hydroxyl group to form a carbonate linkage. Z
and W can be same or different. The preferred Z and W are N-succinimidyl,
1-benzotriazolyl, and p-nitrophenyl. Two or more different bifunctional
oligomers can also be used in the same polymerization reaction.
Methods for preparing such bifunctional oligomers are similar to those for
making the monofunctional oligomers described above. Preferably, Z and W
are the same, and the bifunctional molecule Z-oligomer-Z can be provided
by activating an oligomer having two hydroxyl terminal groups, with an
activating molecule having the formula of Z--O--CO.sub.2--Z. Suitable
examples of the activating molecule include, disuccinimidylcarbonate,
bis(1-benzotriazolyl) carbonate and bis(p-nitrophenyl) carbonate. See,
e.g., U.S. Pat. No. 5,281,698; U.S. Pat. No. 5,650,234; Veronese, et al.,
Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem.
Biotech., 27:45 (1991), all of which are incorporated herein by reference.
In addition to the first oligomer that is bifunctional, a second oligomer
is also provided having two terminal hydroxyl groups. This second oligomer
is then polymerized with the first oligomer to form the polymer of this
invention.
Two or more types of bifunctional oligomers can be used in the same
polymerization reaction. In addition, two or more types of oligomers
having two terminal hydroxyl groups can also be used in a polymerization
reaction. As will be apparent to a skilled artisan, when only one type of
bifunctional oligomer and one type of dihydroxyl oligomer are used, and
when the two oligomers are the same except for the terminal groups, the
polymer formed therefrom will be a homopolymer having a single type of
repeating unit or oligomer linked with hydrolytically degradable linkages.
Otherwise, a heteropolymer or block polymer or terpolymer will be made
containing different types of oligomers in the polymer backbone.
To give an example of the method of this embodiment, the poly(ether
carbonate) HO--[(--CH.sub.2CH.sub.2--O--).sub.n--CO.sub.2--].sub.m--(CH.sub.2CH.sub.-
2O).sub.n--H can be prepared by co-polymerizing a first ethylene oxide
oligomer having a formula of Z--O.sub.2C--O--(--CH.sub.2CH.sub.2--O--).sub.n--CO.sub.2--Z
and a second ethylene oxide oligomer HO--(--CH.sub.2CH.sub.2--O--).sub.n--OH,
under suitable polymerization conditions. Z is preferably N-succinimidyl,
1-benzotriazolyl, or p-nitrophenyl. The oligomer
Z--O.sub.2C--O--(--CH.sub.2CH.sub.2--O--).sub.n--CO.sub.2--Z can be
prepared by reacting Z--O--CO.sub.2--Z with HO--(--CH.sub.2CH.sub.2--O--).sub.n--OH,
under the conditions disclosed in U.S. Pat. No. 5,281,698.
In yet another method, one or more oligomers having two hydroxyl terminal
groups are polymerized directly with an activating molecule having the
formula of Z--O--CO.sub.2--Z to form the hydrolytically degradable
polymer. Thus, for example, the poly(ether carbonate)
HO--[(--CH.sub.2CH.sub.2--O--).sub.n--CO.sub.2--].sub.m--(CH.sub.2CH.sub.-
2O).sub.n--H can also be prepared by co-polymerizing an activating
molecule Z--O--CO.sub.2--Z and the oligomer HO--(--CH.sub.2CH.sub.2--O--).sub.n--OH,
under conditions sufficient to form the poly(ether carbonate).
Again, in this method, either one oligomer is used to generate a
homopolymer, or two or more different oligomers can be used in the same
polymerization reaction to produce a heteropolymer, or block polymer or
terpolymer.
The polymerization reactions are conducted under conditions sufficient to
form the hydrolytically degradable polymer of this invention. The
polymerization reaction in each of the above-described methods is a
condensation reaction. Many different known reaction conditions can be
used. Typically, a catalyst is included in the polymerization reaction
mixture. Examples of suitable catalysts are organic bases, including
triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine. Amine
bases such as 4,4-dimethylaminopyridine and triethylamine are preferred.
The polymerization can be conducted in either melt or solvent. Suitable
solvents include, but are not limited to, acetonitrile, THF,
dimethylformamide, dimethylsulfoxide, benzene, toluene, xylenes,
chloroform, and methylene chloride. The polymerization reaction rate and
the extent of polymerization, which determines the average molecule weight
of the final hydrolytically degradable polymer product can be partly
controlled by the reaction temperature and the reaction time. Suitable
reaction temperature can vary from about 0.degree. C. to 100.degree. C.
Higher reaction temperatures lead to greater reaction speed. Preferably,
the polymerization reaction is conducted at a temperature of from about
37.degree. C. to 100.degree. C., typically from about 45.degree. C. to
100.degree. C. and advantageously from about 70.degree. C. to 90.degree.
C. When the reaction is conducted in a melt, the temperature needs be
maintained at a certain minimum temperature in order to keep the reaction
mixture at a melt state.
In the above described three embodiments of the method of this invention,
the polymerization reactions would be predicted to lead to polymers with
an activated carbonate terminal group. In practice, however, NMR analysis
of the polymer products indicates that the terminal groups of the
hydrolytically degradable polymer prepared therefrom often are hydroxyl
groups. While not wishing to be bound by any theory, it is believed that
this is caused by reaction with a small amount of water present as an
impurity in the reaction. Any small amount of remaining terminally
activated carbonate may be removed by hydrolysis in water for a short
period or near a neutral pH. The terminal activating groups are much more
sensitive to water than are the degradable carbonate linkages.
The polymer of this invention can optionally be activated at one or all
termini, thus providing an activated polymer capable of being covalently
linked to another molecule, including, for example, a protein, to form a
conjugate. The polymer can also be capped at one terminus by an inert
group and at another terminus by a reactive moiety.
The polymer of this invention can be activated at its terminus to form a
terminal reactive moiety by methods well known to those familiar with the
art of organic or polymer chemistry. The well established methods in the
broad field of poly(ethylene glycol) chemistry are generally useful, and
such methods should be apparent to a skilled artisan. The polymer can be
activated at one terminus, or all termini, in which case, the reactive
moieties at different termini can be same or different.
For example, the polymer may be activated to form a terminal moiety of N-succinimidyl
carbonate (see e.g., U.S. Pat. Nos. 5,281,698, 5,468,478), amine (see,
e.g., Buckmann et al. Makromol. Chem. 182:1379 (1981), Zaplipsky et al
Eur. Polym. J. 19:1177 (1983)), hydrazide (See, e.g., Andresz et al.
Makromol. Chem. 179:301 (1978)), succinimidyl propionate and succinimidyl
butanoate (see, e.g., Olson et al. in Poly(ethylene glycol) Chemistry &
Biological Applications, pp 170-181, Harris & Zaplipsky Eds., ACS,
Washington, D.C., 1997; see also U.S. Pat. No. 5,672,662), succinimidyl
succinate (See, e.g., Abuchowski et al. Cancer Biochem. Biophys. 7:175
(1984) and Joppich et al. Macrolol. Chem. 180:1381 (1979), succinimidyl
ester (see, e.g., U.S. Pat. No. 4,670,417), benzotriazole carbonate (see,
e.g., U.S. Pat. No. 5,650,234), glycidyl ether (see, e.g., Pitha et al.
Eur. J. Biochem. 94:11 (1979), Elling et al, Biotech. Appl. Biochem.
13:354 (1991), oxycarbonylimidazole (see, e.g., Beauchamp, et al., Anal.
Biochem. 131:25 (1983), Tondelli et al. J. Controlled Release 1:251
(1985)), p-nitrophenyl carbonate (see, e.g., Veronese, et al., Appl.
Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem.
Biotech., 27:45 (1991)), aldehyde (see, e.g., Harris et al. J. Polym. Sci.
Chem. Ed. 22:341 (1984), U.S. Pat. Nos. 5,824,784, 5,252,714), maleimide
(see, e.g., Goodson et al. Bio/Technology 8:343 (1990), Romani et al. in
Chemistry of peptides and Proteins 2:29 (1984)), and Kogan, Synthetic
Comm. 22:2417 (1992)), orthopyridyl-disulfide (see, e.g., Woghiren, et al.
Bioconj. Chem. 4:314 (1993)), acrylol (see, e.g., Sawhney et al.,
Macromolecules, 26:581 (1993)), vinylsulfone (see, e.g., U.S. Pat. No.
5,900,461). In addition, two molecules of the polymer of this invention
can also be linked to the amino acid lysine to form a di-substituted
lysine, which can then be further activated with N-hydroxysuccinimide to
form an active of N-succinimidyl moiety (see, e.g., U.S. Pat. No.
5,932,462). All of the above references are incorporated herein by
reference.
To give an example, the polymer of this invention may be activated to form
a terminal reactive moiety of N-succinimidyl carbonate or 1-benzotriazolyl
carbonate by reacting the polymer with di-N-succinimidyl carbonate or
di-1-benzotriazolyl carbonate respectively. To give another example,
terminal reactive moieties such as N-maleimidyl and o-pyridyldithiyl may
be prepared by reacting the polymer with activated carbonates connected to
N-maleimidyl or o-pyridyldithiyl by linker groups. Terminal aldehyde and
acetal moieties can be attached by linking groups. Terminal acid groups
can be attached by reaction of the above active carbonates with amino
acids or other acid linkers. These acids can then be activated by
formation of active esters such as succinimidyl active esters.
The polymer of this invention, activated or not, as prepared by the above
methods. can be easily purified from the reaction mixture. Many methods
known in the art can be used. A preferred method for purifying the polymer
and its derivatives is by precipitation from a solvent in which they are
essentially insoluble while the reactants are soluble. Suitable solvents
include ethyl ether or isopropanol. As is apparent to a skilled artisan,
other methods such as ion exchange, size exclusion, silica gel, and
reverse phase chromatography can also be useful.
In accordance with another aspect of this invention, the activated polymer
is used to form a conjugate with a biologically active agent. The
conjugate comprises the polymer of this invention covalently linked to a
biologically active agent. Because the polymer of this invention is
hydrolytically degradable in vivo and can be cleaved at the carbonate
linkages, thus forming smaller oligomers, the conjugate is especially
useful for controlled delivery of the bound agent into animal bodies.
Since the polymer in the conjugate is susceptible to breakdown into
smaller oligomers, the polymer typically is excreted from animal bodies
faster than a polymer of similar size that is not degradable. Thus,
potential adverse effects that may be caused by a large polymer's long
period of stay in the body is avoided. Therefore, conjugation of the
polymer of this invention to a biologically active agent can provide for a
sufficient circulation period for the agent while minimizing any adverse
effects of the polymer.
In the conjugates of this invention, the linkage between the biologically
active agent and the polymer of this invention can be stable or
hydrolytically degradable. When it is degradable, substantially all of the
polymer can be cleaved off the biologically active agent under
physiological conditions, releasing the agent substantially in its native
form inside the body. Methods for forming a hydrolytically degradable
linkage between a biologically active agent and a water soluble polymer
are well known in the art and should be apparent to a skilled artisan. For
example, ester linkages formed by the reaction of PEG carboxylic acids or
activated PEG carboxylic acids with alcohol groups on a biologically
active agent generally hydrolyze under physiological conditions to release
the agent. Other hydrolytically degradable linkages include carbonate
linkages; imine linkages resulted from reaction of an amine and an
aldehyde (see, e.g., Ouchi et al., Polymer Preprints, 38(1):582-3 (1997),
which is incorporated herein by reference.); phosphate ester linkages
formed by reacting an alcohol with a phosphate group; hydrozone linkages
which are reaction product of a hydrazide and an aldehyde; acetal linkages
that are the reaction product of an aldehyde and an alcohol; orthoester
linkages that are the reaction product of a formate and an alcohol;
peptide linkages formed by an amine group, e.g., at an end of a polymer
such as PEG, and a carboxyl group of a peptide; and oligonucleotide
linkages formed by a phosphoramidite group, e.g., at the end of a polymer,
and a 5' hydroxyl group an oligonucleotide.
Methods for conjugating the polymer of this invention to a biologically
active agent should be apparent based on the above discussion. Typically,
the polymer of this invention must be activated to form the activated
polymer of this invention as described above, having at least one terminal
reactive moiety. The terminal reactive moiety may vary depending on the
reactivity of a target moiety on the biologically active agent to be
conjugated. Examples of reactive groups on proteins are thiols and amines,
while on small molecule drugs, amines, alcohols, thiols, and carboxylic
acids are common reactive groups. The conjugate is then formed by reacting
the terminal reactive moiety of the activated polymer with the target
moiety on the biologically active agent. Such methods are well known in
the art, and are discussed in the patents and publications referred to
above in the context of forming terminal reactive moieties.
In a preferred embodiment, the polymer of this invention used for forming
a conjugate is a poly(ether carbonate) composed of alkylene oxide
oligomers, more preferably ethylene oxide oligomers, linked together by
carbonate linkages. Ethylene oxide oligomers are poly(ethylene glycol)s
with a predetermined molecular weight, typically from about 88 to about
8000, preferably from about 88 to about 2000. Thus, in this embodiment of
the invention, the polymer behaves in a similar manner as polyethylene
glycol. However, when delivered in vivo, the polymer in the conjugate will
break down into a number of smaller oligomer fragments. If the linkage
between the polymer and the biologically active agent is stable, then,
after degradation, one oligomer is linked to the agent.
In accordance with another aspect of this invention, a hydrolytically
degradable hydrogel and method of making thereof are also provided. As is
known in the art, a hydrogel typically is a polymeric network formed by
crosslinking one or more multifunctional backbone molecules or polymers.
The resulting polymeric network is hydrophilic and swells in an aqueous
environment thus forming a gel-like material, i.e., hydrogel. Hydrogels
are useful for drug delivery as they can be implanted or injected into
animal bodies. Typically a hydrogel comprises a backbone bonded to a
crosslinking agent.
In accordance with this invention, the polymer of this invention is used
as the crosslinking agent in the hydrogel. The polymer must be activated
so that it has at least two terminal reactive moieties that are capable of
reacting with multiple moieties on the backbone to form covalent linkages.
Alternatively, two or more types of activated polymer are used as
crosslinking agents. Each activated polymer has one terminal reactive
moiety capable of reacting with a moiety on the backbone, and another
terminal reactive moiety capable of reacting with the corresponding
terminal reactive moiety on the other type of activated polymer. An
example of this other moiety is, for example, a vinyl-containing group
such as an acrylate group that can participate in chain polymerization
among the different types of activated polymers. When the polymer of this
invention is activated so that it has two terminal vinyl groups, the
polymer itself may act as both crosslinking agent and backbone, and
self-polymerize into a hydrolytically degradable hydrogel through a chain
polymerization reaction.
The backbone of the hydrogel is a nontoxic biocompatible macromolecule or
small molecule, having at least two or preferably more active groups
available to react with the terminal reactive moieties of the crosslinking
agent to form covalent linkages. By "biocompatible" it is intended that
the molecule used as backbone would not substantially adversely affect the
body and tissue of the living subject into which the hydrogel is to be
implanted or injected. More particularly, the material does not
substantially adversely affect the growth and any other desired
characteristics of the tissue cells surrounding the implanted hydrogel. It
is also intended that the material used does not cause any substantially
medically undesirable effect in any other parts of the living subject. In
addition, if the molecule is degradable inside the body, the degradation
products should also be substantially biocompatible as defined above.
Generally, the methods for testing the biocompatibility of a material well
known in the art.
Examples of suitable backbones include, but are not limited to, proteins,
modified proteins such as glycoproteins, phosphorylated proteins, acylated
proteins, and chemically modified proteins, peptides, aminocarbohydrates,
glycosaminoglycans, aminolipids, polyols, polythiols, polycarboxylic
acids, polyamines such as dilysine, poly(vinylamine) and polylysine,
poly(ethylene glycol) amines, pharmaceutical agents having at least two
active groups, etc. Specific examples of the backbone include, but are not
limited to, branched PEG amines, fibrin, fibrinogen, thrombin, albumins,
globulins, collagens, fibronectin, chitosan, and the like. In addition,
the backbone may also be microorganisms such as viral particles, bacterial
or yeast cells, animal or human cells or tissues.
The activated polymer of this invention used as a crosslinking agent can
be in a linear, branched or star form. In branched or star forms, three or
more linear polymers are covalently linked, at one terminus, to a central,
branched core moiety. The central branch core moiety can be derived from
the amino acid lysine, or polyols such as glycerol, pentaerythritol and
sorbitol. Branched PEGs are known in the art. These branched PEGs can be
incorporated as components of the poly(ether carbonate)s of this
invention.
As will be apparent, because of the carbonate linkages incorporated in the
crosslinking agent, the hydrogel of this invention is hydrolytically
degradable. In addition, the linkages between the backbones and the
crosslinking agents formed from the crosslinking reactions can also be
made hydrolyzable, by methods described in the context of the conjugate of
this invention. Thus, the hydrogel of this invention can gradually break
down or degrade in the body as a result of the hydrolysis of the
hydrolytically degradable linkages.
Therefore, the hydrogel of this invention is suitable as a biomedical
material and a carrier for the delivery of biologically active agents. For
example, the hydrogel can carry therapeutic drugs and can be implanted or
injected in the target area of the body. The hydrogel may also carry other
agents such as nutrients or labeling agents for imaging analysis. A
hydrogel containing a biologically active agent is termed herein as "a
delivery system".
In the various applications of the hydrogel of this invention, the
biologically active agents to be delivered can be used as the backbone, or
part of the backbone of the hydrogel. Alternatively, biologically active
agents can be "hinged" to the hydrogel through a polymer of this invention
or a linker molecule with one terminus of the polymer or the linker linked
to the biologically active agent, and the other being connected through a
covalent linkage to the hydrogel. In addition, biologically active agents
or other substances to be delivered can also be loaded into the hydrogel
during the formation of the hydrogel, or afterwards by, for example,
diffusion into the matrix of the hydrogel without being covalently bonded
to the hydrogel structure.
Because the crosslinking agents (i.e., the polymers of this invention) in
the hydrogel are water soluble, the hydrogel can be substantially water
swellable. The degradation or breakdown of the hydrogel in the body is
gradual in nature and subject to control because of the hydrolytically
degradable carbonate linkages in the crosslinking agents. Thus, the
hydrogels of the invention are particularly useful for sustained release
of a biologically active agent or other substance in the body. The
hydrogels have potential utility for adhesion prevention, bioadhesives,
surgical sealants, and related surgical applications.
Claim 1 of 10 Claims
1. A conjugate of a biologically active
agent and a polyalkylene oxide-based water soluble polymer in activated
form, wherein the polyalkylene oxide-based water soluble polymer comprises
multiple carbonate linkages in a backbone and, for each carbonate linkage
in the backbone, an oligomer linked thereto by the carbonate linkage,
wherein the oligomer is branched and, prior to being linked by the
carbonate linkage, has the formula: R.sub.3[O--(--CHR.sub.1CH.sub.2--O--).sub.n--].sub.mH
where R.sub.3 is a core branching moiety, R.sub.1 is H, (n) can range from
2 to 2000, and m is at least 3.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|